Document is current
Any future updates will be listed below
-
Authors
Kannenkeril, Dennis
Bosch, Agnes
Harazny, Joanna
Karg, Marina
Jung, Susanne
Ott, Christian
Schmieder, Roland E. https://orcid.org/0000-0003-2356-5883
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02471963 at ClinicalTrials.govnct01319357 at ClinicalTrials.govDocuments that mention this clinical trial
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
https://doi.org/10.1186/s12933-019-0839-8
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4
nct02383238 at ClinicalTrials.govDocuments that mention this clinical trial
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4
nct00152698 at ClinicalTrials.govDocuments that mention this clinical trial
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
https://doi.org/10.1186/s12933-017-0654-z
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
https://doi.org/10.1186/s12933-017-0510-1
nct00136188 at ClinicalTrials.govDocuments that mention this clinical trial
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4
Documents that mention this clinical trial
Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
https://doi.org/10.1186/s12933-018-0770-4
-
Funding
Funding for this research was provided by:
Medizinische Fakultät, Friedrich-Alexander-Universität Erlangen-Nürnberg
- License Information
-
More Information
Article History
Received: 6 August 2018
Accepted: 14 September 2018
First Online: 19 September 2018
